68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

Launched by MAYO CLINIC · Jan 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 68Ga-PSMA PET to see if it can help doctors better diagnose and manage advanced liver cancer. In this trial, the researchers are focusing on patients whose liver cancer has spread and cannot be treated with surgery or other standard methods. The 68Ga-PSMA is a special substance that targets liver cancer cells, allowing doctors to see where the cancer is located in the body using a PET scan. This could potentially lead to more effective treatment plans for patients.

To participate in this study, patients must be 18 years or older and have confirmed advanced liver cancer that can't be surgically removed. They should also be eligible for specific front-line treatments. However, pregnant or breastfeeding individuals cannot join, and there are size limitations for the imaging equipment. Participants can expect to undergo the PET scan and contribute to research that may improve future care for liver cancer patients. This trial is currently looking for volunteers to help advance our understanding of this disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with pathologically confirmed HCC not amenable to curative resection, transplantation or ablative therapies
• • Have radiographically measurable disease by RECIST
• • Eligible for atezolizumab/bevacizumab front line therapy
• • Male or female with age greater than 18 years, with the capacity and willingness to provide written informed consent
• Exclusion Criteria:
• • Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of the PET scan
• • Patients with higher than the weight/size limitations of PET/CT scanner